3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Cisplatin
30
Radiotherapy
24
pembrolizumab
21
Cetuximab
21
Docetaxel
13
Fluorouracil
12
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Radiation
8
Nivolumab
7
Everolimus
7
Carboplatin
7
Oxaliplatin
6
Gemcitabine
5
Surgical Procedures, Operative
4
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
Gefitinib
4
Erlotinib Hydrochloride
4
Amifostine
4
Pemetrexed
3
Filgrastim
3
Capecitabine
3
Bleomycin
3
Biopsy
3
zalutumumab
2
spartalizumab
2
pegfilgrastim
2
niraparib
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Head and Neck Neoplasms
×
niraparib
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts